Abstract:

Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor. It can inhibit the breakdown of endogenous natriuretic peptides and block angiotensin receptors, thereby reducing the activation of the renin-angiotensin-aldosterone system. It can also promote myocardial remodeling, inhibit myocardial fibrosis, increase the glomerular filtration rate, and delay the deterioration of renal function. Sacubitril/valsartan is beneficial to patients with chronic kidney disease by reducing cardiovascular risk and delaying the progression of chronic kidney disease. As a result, sacubitril/valsartan is one of the important drugs for heart failure, hypertension, and uremia. However, its long-term use may also cause some adverse reactions, especially kidney damage. There are few reports on the application of sacubitril/valsartan in patients with end-stage of renal disease and heart failure. The purpose of this study is to observe the application of sacubitril/valsartan in maintenance dialysis patients with heart failure, to investigate its safety, and to provide references for researches in relevant fields.

Key words:

Heart failure, Dialysis, Sacubitril/valsartan, End-stage renal disease, Progress

摘要：

沙库巴曲缬沙坦作为一种具有抑制血管紧张素受体脑啡肽分解作用的药物，能够有效地阻断血管紧张素受体并抑制利钠肽分解，进而降低肾素-血管紧张素-醛固酮系统的激活水平。同时，能促进心肌结构的重构，抑制心肌纤维化的发生，还能显著提高肾小球滤过率，延缓肾功能的恶化。沙库巴曲缬沙坦的药物成分能够有效地降低患者的心血管风险，同时延缓慢性肾脏病的进展，从而对患者的身体健康产生积极的影响。因此，沙库巴曲缬沙坦是应用于心力衰竭、高血压及尿毒症等疾病的重要药物之一，但长期使用也可能会引起一些不良反应，特别是肾脏损害。目前，对于沙库巴曲缬沙坦应用于终末期肾病合并心力衰竭患者中的报道较少，本综述旨在探究其在维持性透析合并心力衰竭患者中的应用情况，并对其安全性进行评估，以期为相关领域的研究提供参考。

关键词:

心力衰竭, 透析, 沙库巴曲缬沙坦, 终末期肾病, 进展